Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of TissueGene-C to Degenerative Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female, aged 45 years or more~2. With grade 4 degenerative arthritis of the knee \[based on the International Cartilage Repair Society(ICRS) evaluation criteria from the MRI results\]~3. With less than 6 cm2major lesions~4. With major lesions (grade 4) concentrated in only one section of the knee and considered the main cause of the clinical symptoms~5. Unresponsive to conventional symptomatic treatment~6. Healthy and with no major physical examination, hematology, serum chemistry, and urine test findings and no significant medical history~7. Agreed to use an effective contraceptive method during the study period~8. Voluntarily agreed to participate in this study and signed the Informed Consent Form~Exclusion Criteria:~1. Abnormal screening laboratory test (hematology, serum, and urine test) findings~2. Took anti-inflammatory medications (prescribed or over-the-counter), including natural medicines, within 14 days before the injection of the investigational product~3. Took antirheumatic drugs (e.g., methotrexate or antimetabolites) within three months before enrollment in this study~4. Has a history of drug abuse within one year from the enrolment, or has positive results in the urine drug test or serum alcohol test at the screening visit~5. Received an injection in the target knee within two months before enrollment in this study~6. Pregnant or breastfeeding female~7. With another joint disease apart from degenerative arthritis (e.g., systemic rheumatic inflammatory disease associated with the knee or chondrocalcinosis, hemachromatosis, inflammatory arthritis, necrosis of the trochanter, Paget's disease adjacent to a joint in the femur or tibia, ochronosis, hemophilic arthropathy, infectious arthritis, Charcot's disease in the knee joint, villonodular synovitis, and synovial chondromas)~8. With a current infectious disease, including HIV or hepatitis~9. Has any of the following clinically significant diseases:~   * heart disease \[e.g., myocardial infarction, arrhythmia, other serious heart disease, coronary artery bypass graft (CABG)\]~  * kidney disease (e.g., chronic renal failure, glomerulonephritis)~  * liver disease (e.g., liver cirrhosis, fatty liver, acute or chronic liver disease)~  * endocrine disease (e.g., hyperthyroidism, hypothyroidism, thyroiditis, diabetes insipidus, Cushing's disease)~  * insulin-dependent diabetes mellitus~  * medical history of or current malignant tumor~  * In particular, the tumors that TissueGene-C may aggravate can be screened using the following tests:~     * Leukemia: White Blood Cell level in the hematology~    * Osteochondroma, Chondromas, Chondroblastoma, Chondromyxoid fibroma, Chondrosarcoma : Alkaline phosphatase level in the hematology~10. Participated in another clinical trial (using the investigational drug or a medical device) within 30 days before enrollment in this study~11. Considered by the investigator inappropriate for participation in this study

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TissueGene-C (Low dose) (Type: EXPERIMENTAL): Single intra-articular injection to the damaged knee joint at a dose of 6.0 x 10\^6 cells
- TissueGene-C (High dose) (Type: EXPERIMENTAL): Single intra-articular injection to the damaged knee joint at a dose of 1.8 x 10\^7 cells

Based on this trial design, predict the completion outcome and termination type (if applicable).